title: Expanding the Reach of Anti-PD-1 Therapy.
abstract: Results from three studies, including KEYNOTE-012 and CheckMate 057, indicate that anti-PD-1 drugs look promising in cancers other than melanoma. Pembrolizumab was twice as effective as cetuximab for advanced head and neck squamous cell carcinoma; nivolumab induced durable antitumor activity in advanced liver cancer; and nivolumab extended the median overall survival of patients with advanced non-squamous non-small cell lung cancer.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics; D000068818:Cetuximab / Q000627:therapeutic use; D000068456:Clinical Studies as Topic; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab; D000068818:Cetuximab